Avalo Therapeutics
AVTX
34 hedge funds and large institutions have $66.1M invested in Avalo Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
18% more capital invested
Capital invested by funds: $56M → $66.1M (+$10.2M)
5.37% more ownership
Funds ownership: 71.99% → 77.37% (+5.4%)
3% more funds holding
Funds holding: 33 → 34 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.82M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.94M |
| 3 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$2.37M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$806K |
| 5 |
AI
Allostery Investments
Stamford,
Connecticut
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.84M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$1.22M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$888K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$446K |
| 5 |
HF
HRT Financial
New York
|
-$225K |
AVTX Hedge Fund Activity: Q1 2025 in Review
34 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2025, worth a combined $66.1M — up 18% from $56M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AVTX positions and 4 closed out — a net gain of 1 holder — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $6.82M. The largest seller was Ikarian Capital, cutting an estimated $5.84M.
- 34 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2025, up from 33 in Q4 2024.
- Funds reported $66.1M of Avalo Therapeutics stock for Q1 2025, up 18% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q1 2025 and 4 closed out, a net change of +1 holder.
- The largest Avalo Therapeutics buyer in Q1 2025 was Nantahala Capital Management, an estimated $6.82M added.
- The largest Avalo Therapeutics seller in Q1 2025 was Ikarian Capital, an estimated $5.84M sold.
Based on aggregated 13F filings for Q1 2025.